Biosyn Healthcare

biosyn Arzneimittel GmbH is a specialized German pharmaceutical and biotechnology company that has established itself as a global leader in trace element therapy and high-purity Keyhole Limpet Hemocyanin (KLH). Founded in 1984 and headquartered in Fellbach, the company focuses on the development and manufacture of products for oncology, intensive care, and immunology. Its flagship product, selenase, is a widely used sodium selenite formulation for treating selenium deficiency in critically ill patients, particularly those with sepsis. Additionally, biosyn is a premier provider of GMP-grade KLH (marketed as IMMUNOCYTHEL and vacmune), which serves as a therapeutic agent for bladder cancer and a critical carrier protein for the next generation of therapeutic vaccines. As a privately held, vertically integrated company, biosyn maintains its own research and production facilities, supporting a global distribution network across over 25 countries.